Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sana Biotechnology, Inc.SANA · Entity 4870 | See Remarks | March 06, 2026 | March 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sana Biotechnology, Inc.
Report date March 06, 2026 · Filed March 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 196,196 |
Ending reported balance
After 2026-03-09 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-03-06 · Exercise / conversion · Acquired 10,416 · Balance 197,333 Row 2 · 2026-03-07 · Exercise / conversion · Acquired 3,250 · Balance 200,583 Row 3 · 2026-03-09 · Tax withholding · Disposed 3,342 · Balance 197,241 Row 4 · 2026-03-09 · Tax withholding · Disposed 1,045 · Balance 196,196 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 31,251 |
Reported balance
After 2026-03-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-06 · Exercise / conversion · Disposed 10,416 · Balance 31,251 F1: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock. F2: The award vested as to 25% of the restricted stock units on March 6, 2026, and the remaining restricted stock units will vest in three equal installments on each of March 6, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 6,500 |
Reported balance
After 2026-03-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-03-07 · Exercise / conversion · Disposed 3,250 · Balance 6,500 F1: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock. F3: The award vested as to 25% of the restricted stock units on each of March 7, 2025 and 2026, and the remaining restricted stock units will vest in two equal installments on each of March 7, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.
F2: The award vested as to 25% of the restricted stock units on March 6, 2026, and the remaining restricted stock units will vest in three equal installments on each of March 6, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
F3: The award vested as to 25% of the restricted stock units on each of March 7, 2025 and 2026, and the remaining restricted stock units will vest in two equal installments on each of March 7, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 09, 2026 Filed Mar 10, 2026 16:15 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Tax withholdingCommon Stock | 1,045 | $3.10 | $3,239.50 |
DisclosureSEC source: 0001568605-26-000008 · primarydocument.xml · nonDerivative · entry 4 Wyrick Susan D. · CIK 0001568605 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,196 Read SEC document |
| March 09, 2026 Filed Mar 10, 2026 16:15 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Tax withholdingCommon Stock | 3,342 | $3.13 | $10,460.46 |
DisclosureSEC source: 0001568605-26-000008 · primarydocument.xml · nonDerivative · entry 3 Wyrick Susan D. · CIK 0001568605 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197,241 Read SEC document |
| March 07, 2026 Filed Mar 10, 2026 16:15 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Exercise / conversionRestricted Stock Units · Derivative | 3,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001568605-26-000008 · primarydocument.xml · derivative · entry 6 Wyrick Susan D. · CIK 0001568605 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 3,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock. F3 · derivative.exercise_date: The award vested as to 25% of the restricted stock units on each of March 7, 2025 and 2026, and the remaining restricted stock units will vest in two equal installments on each of March 7, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. F3 · derivative.expiration_date: The award vested as to 25% of the restricted stock units on each of March 7, 2025 and 2026, and the remaining restricted stock units will vest in two equal installments on each of March 7, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. Read SEC document |
| March 07, 2026 Filed Mar 10, 2026 16:15 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Exercise / conversionCommon Stock | 3,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001568605-26-000008 · primarydocument.xml · nonDerivative · entry 2 Wyrick Susan D. · CIK 0001568605 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 16:15 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Exercise / conversionRestricted Stock Units · Derivative | 10,416 | $0.00 | $0.00 |
DisclosureSEC source: 0001568605-26-000008 · primarydocument.xml · derivative · entry 5 Wyrick Susan D. · CIK 0001568605 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,251 Underlying: Common Stock · 10,416 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock. F2 · derivative.exercise_date: The award vested as to 25% of the restricted stock units on March 6, 2026, and the remaining restricted stock units will vest in three equal installments on each of March 6, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. F2 · derivative.expiration_date: The award vested as to 25% of the restricted stock units on March 6, 2026, and the remaining restricted stock units will vest in three equal installments on each of March 6, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 16:15 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Exercise / conversionCommon Stock | 10,416 | $0.00 | $0.00 |
DisclosureSEC source: 0001568605-26-000008 · primarydocument.xml · nonDerivative · entry 1 Wyrick Susan D. · CIK 0001568605 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 16:53 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 206,250 | $0.00 Strike: $3.41 | $0.00 |
DisclosureSEC source: 0001568605-26-000006 · primarydocument.xml · derivative · entry 2 Wyrick Susan D. · CIK 0001568605 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,250 Underlying: Common Stock · 206,250 shares Expires 2036-03-04 F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on March 5, 2027 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 16:53 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantRestricted Stock Units · Derivative | 45,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001568605-26-000006 · primarydocument.xml · derivative · entry 1 Wyrick Susan D. · CIK 0001568605 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,833 Underlying: Common Stock · 45,833 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock. F2 · derivative.exercise_date: The restricted stock units vest in four equal installments on each of March 5, 2027, 2028, 2029 and 2030, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. F2 · derivative.expiration_date: The restricted stock units vest in four equal installments on each of March 5, 2027, 2028, 2029 and 2030, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. Read SEC document |
| March 03, 2026 Filed Mar 4, 2026 16:17 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Tax withholdingCommon Stock | 491 | $3.91 | $1,919.81 |
DisclosureSEC source: 0001568605-26-000004 · primarydocument.xml · nonDerivative · entry 2 Wyrick Susan D. · CIK 0001568605 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,917 Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 16:17 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Exercise / conversionRestricted Stock Units · Derivative | 1,525 | $0.00 | $0.00 |
DisclosureSEC source: 0001568605-26-000004 · primarydocument.xml · derivative · entry 3 Wyrick Susan D. · CIK 0001568605 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,525 Underlying: Common Stock · 1,525 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock. F2 · derivative.exercise_date: The award vested as to 25% of the restricted stock units on each of March 2, 2024, 2025 and 2026, and the remaining restricted stock units will vest on March 2, 2027, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date. F2 · derivative.expiration_date: The award vested as to 25% of the restricted stock units on each of March 2, 2024, 2025 and 2026, and the remaining restricted stock units will vest on March 2, 2027, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 16:17 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Exercise / conversionCommon Stock | 1,525 | $0.00 | $0.00 |
DisclosureSEC source: 0001568605-26-000004 · primarydocument.xml · nonDerivative · entry 1 Wyrick Susan D. · CIK 0001568605 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,408 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 16:18 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Tax withholdingCommon Stock | 2,407 | $4.27 | $10,277.89 |
DisclosureSEC source: 0001568605-26-000002 · primarydocument.xml · nonDerivative · entry 2 Wyrick Susan D. · CIK 0001568605 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,883 Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 16:18 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Exercise / conversionRestricted Stock Units · Derivative | 7,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001568605-26-000002 · primarydocument.xml · derivative · entry 3 Wyrick Susan D. · CIK 0001568605 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. common stock. F2 · derivative.exercise_date: The award vested as to 40% of the restricted stock units on January 2, 2025 and 60% of the restricted stock units on January 2, 2026. F2 · derivative.expiration_date: The award vested as to 40% of the restricted stock units on January 2, 2025 and 60% of the restricted stock units on January 2, 2026. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 16:18 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Exercise / conversionCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001568605-26-000002 · primarydocument.xml · nonDerivative · entry 1 Wyrick Susan D. · CIK 0001568605 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 16:16 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Tax withholdingCommon Stock | 873 | $5.22 | $4,557.06 |
DisclosureSEC source: 0001568605-25-000007 · primarydocument.xml · nonDerivative · entry 2 Wyrick Susan D. · CIK 0001568605 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,790 Read SEC document |
| December 13, 2025 Filed Dec 16, 2025 16:16 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Exercise / conversionRestricted Stock Units · Derivative | 3,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001568605-25-000007 · primarydocument.xml · derivative · entry 3 Wyrick Susan D. · CIK 0001568605 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. common stock. F2 · derivative.exercise_date: The award vested as to 100% of the restricted stock units on December 13, 2025. F2 · derivative.expiration_date: The award vested as to 100% of the restricted stock units on December 13, 2025. Read SEC document |
| December 13, 2025 Filed Dec 16, 2025 16:16 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Exercise / conversionCommon Stock | 3,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001568605-25-000007 · primarydocument.xml · nonDerivative · entry 1 Wyrick Susan D. · CIK 0001568605 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,663 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 17:04 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Tax withholdingCommon Stock | 2,565 | $4.44 | $11,388.60 |
DisclosureSEC source: 0001568605-25-000005 · primarydocument.xml · nonDerivative · entry 4 Wyrick Susan D. · CIK 0001568605 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,263 Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 17:04 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Exercise / conversionRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001568605-25-000005 · primarydocument.xml · derivative · entry 8 Wyrick Susan D. · CIK 0001568605 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana common stock. F7 · derivative.exercise_date: The restricted stock units vested in two equal installments on each of June 3, 2025 and December 3, 2025. F7 · derivative.expiration_date: The restricted stock units vested in two equal installments on each of June 3, 2025 and December 3, 2025. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 17:04 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Exercise / conversionCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001568605-25-000005 · primarydocument.xml · nonDerivative · entry 3 Wyrick Susan D. · CIK 0001568605 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,828 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · balance_after: Includes 3,000 shares acquired on November 14, 2025 pursuant to the ESPP. Read SEC document |
| June 04, 2025 Filed Dec 5, 2025 17:04 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Tax withholdingCommon Stock | 2,567 | $2.32 | $5,955.44 |
DisclosureSEC source: 0001568605-25-000005 · primarydocument.xml · nonDerivative · entry 2 Wyrick Susan D. · CIK 0001568605 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 167,828 F1 · date: This transaction is being reported late due to an inadvertent administrative error and not any error of the reporting person. Read SEC document |
| June 03, 2025 Filed Dec 5, 2025 17:04 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Exercise / conversionRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001568605-25-000005 · primarydocument.xml · derivative · entry 7 Wyrick Susan D. · CIK 0001568605 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana common stock. F1 · date: This transaction is being reported late due to an inadvertent administrative error and not any error of the reporting person. F7 · derivative.exercise_date: The restricted stock units vested in two equal installments on each of June 3, 2025 and December 3, 2025. F7 · derivative.expiration_date: The restricted stock units vested in two equal installments on each of June 3, 2025 and December 3, 2025. Read SEC document |
| June 03, 2025 Filed Dec 5, 2025 17:04 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Exercise / conversionCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001568605-25-000005 · primarydocument.xml · nonDerivative · entry 1 Wyrick Susan D. · CIK 0001568605 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,395 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: This transaction is being reported late due to an inadvertent administrative error and not any error of the reporting person. F2 · balance_after: Includes 3,000 shares acquired on May 15, 2025 pursuant to Sana Biotechnology, Inc.'s ("Sana") 2021 Employee Stock Purchase Plan (the "ESPP"). Read SEC document |
| March 10, 2025 Filed Mar 10, 2025 20:13 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Tax withholdingCommon Stock | 836 | $2.56 | $2,140.16 |
DisclosureSEC source: 0001562180-25-002274 · primarydocument.xml · nonDerivative · entry 2 Wyrick Susan D. · CIK 0001568605 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,395 Read SEC document |
| March 07, 2025 Filed Mar 10, 2025 20:13 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Exercise / conversionRestricted Stock Units · Derivative | 3,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-002274 · primarydocument.xml · derivative · entry 5 Wyrick Susan D. · CIK 0001568605 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,750 Underlying: Common Stock · 3,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock. F4 · derivative.exercise_date: The award vested as to 25% of the restricted stock units on March 7, 2025 and the remaining restricted stock units will vest in three equal installments on each of March 7, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. F4 · derivative.expiration_date: The award vested as to 25% of the restricted stock units on March 7, 2025 and the remaining restricted stock units will vest in three equal installments on each of March 7, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. Read SEC document |
| March 07, 2025 Filed Mar 10, 2025 20:13 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Exercise / conversionCommon Stock | 3,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-002274 · primarydocument.xml · nonDerivative · entry 1 Wyrick Susan D. · CIK 0001568605 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 20:13 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 187,500 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001562180-25-002274 · primarydocument.xml · derivative · entry 4 Wyrick Susan D. · CIK 0001568605 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,500 Underlying: Common Stock · 187,500 shares Expires 2035-03-05 F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on March 6, 2026 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 20:13 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantRestricted Stock Units · Derivative | 41,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-002274 · primarydocument.xml · derivative · entry 3 Wyrick Susan D. · CIK 0001568605 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,667 Underlying: Common Stock · 41,667 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock. F2 · derivative.exercise_date: The restricted stock units vest in four equal installments on each of March 6, 2026, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. F2 · derivative.expiration_date: The restricted stock units vest in four equal installments on each of March 6, 2026, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. Read SEC document |
| March 03, 2025 Filed Mar 3, 2025 19:28 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Tax withholdingCommon Stock | 490 | $2.56 | $1,254.40 |
DisclosureSEC source: 0001562180-25-001888 · primarydocument.xml · nonDerivative · entry 2 Wyrick Susan D. · CIK 0001568605 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,981 Read SEC document |
| March 02, 2025 Filed Mar 3, 2025 19:28 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Exercise / conversionRestricted Stock Units · Derivative | 1,525 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-001888 · primarydocument.xml · derivative · entry 3 Wyrick Susan D. · CIK 0001568605 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,050 Underlying: Common Stock · 1,525 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock. F2 · derivative.exercise_date: The award vested as to 25% of the restricted stock units on each of March 2, 2024 and 2025, and the remaining restricted stock units vest in two equal installments on each of March 2, 2026 and 2027, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. F2 · derivative.expiration_date: The award vested as to 25% of the restricted stock units on each of March 2, 2024 and 2025, and the remaining restricted stock units vest in two equal installments on each of March 2, 2026 and 2027, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. Read SEC document |
| March 02, 2025 Filed Mar 3, 2025 19:28 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Exercise / conversionCommon Stock | 1,525 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-001888 · primarydocument.xml · nonDerivative · entry 1 Wyrick Susan D. · CIK 0001568605 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,471 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 16:15 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Exercise / conversionRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000105 · primarydocument.xml · derivative · entry 3 Wyrick Susan D. · CIK 0001568605 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana common stock. F3 · derivative.exercise_date: The award vested as to 40% of the restricted stock units on January 2, 2025 and the remaining 60% of the restricted stock units will vest on January 2, 2026, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date. F3 · derivative.expiration_date: The award vested as to 40% of the restricted stock units on January 2, 2025 and the remaining 60% of the restricted stock units will vest on January 2, 2026, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 16:15 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Tax withholdingCommon Stock | 1,566 | $1.65 | $2,583.90 |
DisclosureSEC source: 0001562180-25-000105 · primarydocument.xml · nonDerivative · entry 2 Wyrick Susan D. · CIK 0001568605 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,946 Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 16:15 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Exercise / conversionCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000105 · primarydocument.xml · nonDerivative · entry 1 Wyrick Susan D. · CIK 0001568605 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 3,000 shares acquired on November 15, 2024 pursuant to Sana Biotechnology, Inc.'s ("Sana") 2021 Employee Stock Purchase Plan. Read SEC document |
| December 13, 2024 Filed Dec 5, 2025 17:04 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 5,100 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001568605-25-000005 · primarydocument.xml · derivative · entry 6 Wyrick Susan D. · CIK 0001568605 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,100 Underlying: Common Stock · 5,100 shares Expires 2034-12-12 F1 · date: This transaction is being reported late due to an inadvertent administrative error and not any error of the reporting person. F6 · derivative.exercise_date: The option vests as to 100% of the shares underlying the option on January 13, 2026, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date. Read SEC document |
| December 13, 2024 Filed Dec 5, 2025 17:04 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantRestricted Stock Units · Derivative | 3,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001568605-25-000005 · primarydocument.xml · derivative · entry 5 Wyrick Susan D. · CIK 0001568605 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,400 Underlying: Common Stock · 3,400 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana common stock. F1 · date: This transaction is being reported late due to an inadvertent administrative error and not any error of the reporting person. F5 · derivative.exercise_date: The award vests as to 100% of the restricted stock units on December 13, 2025, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date. F5 · derivative.expiration_date: The award vests as to 100% of the restricted stock units on December 13, 2025, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.